GeneDx Holdings Corp. (NASDAQ: WGS), a publicly traded clinical genomics company, faces a securities class action lawsuit alleging that executives misrepresented the strategic and financial benefits of acquiring Fabric Genomics in May 2025, then concealed integration failures that destroyed shareholder value. The class action, Taher Basma v.
GeneDx Holdings Corp., alleges fraud under the Securities Exchange Act, and while the deadline to serve as lead plaintiff expired August 3, 2026, investors with losses exceeding $100,000 can still participate in the class without filing a separate claim. The lawsuit covers investors who purchased GeneDx stock between April 16, 2025 and May 4, 2026, the date the company revealed a $31.3 million non-cash impairment tied to the acquisition and slashed full-year revenue guidance by 12 percent. The stock collapsed 49 percent that day, and multiple law firms are managing claims on a contingent-fee basis—meaning investors pay nothing upfront and only share in recoveries.
Official resources:
- SEC EDGAR 10-Q — Use this primary source to review the underlying data.
- Read the official notice from SEC — Use this primary source to verify the official announcement.
Table of Contents
- The Company and the Acquisition
- What the Allegations Claim
- The Financial Disclosures That Exposed the Problem
- The Stock Collapse and Investor Losses
- Who Can Still Join and What It Costs
- Important Limits and Realities
- Frequently Asked Questions
The Company and the Acquisition
GeneDx operates a clinical genomics platform with roughly 75,000 clinician users who rely on whole-exome and whole-genome sequencing to diagnose rare and inherited diseases. According to the company's business description, this service generates revenue through reimbursement and direct patient testing.
In May 2025, GeneDx announced it was acquiring Fabric Genomics—a data analytics and interpretation platform—for up to $51 million in consideration. The deal was publicly positioned as a strategic expansion to strengthen GeneDx's diagnostic capabilities and drive future growth. However, integration did not proceed as management had represented to investors.
What the Allegations Claim
The lawsuit alleges that GeneDx misrepresented the strategic and financial benefits of the Fabric Genomics acquisition, concealing integration challenges and performance shortfalls. The complaint asserts that executives knew, or should have known, that the acquisition was underperforming—but did not disclose those problems to investors during the class period.
The allegation rests on undisclosed facts, not hindsight: the company's own filings show management was tracking performance and realization of synergies. If executives concealed known problems, that silence during the class period would constitute securities fraud. The case proceeds through standard motion practice, meaning discovery will test these allegations before any settlement or trial.
The Financial Disclosures That Exposed the Problem
On May 4, 2026, GeneDx announced Q1 2026 results and reported a $31.3 million non-cash impairment directly tied to Fabric Genomics, along with a decline in adjusted gross margin from 74 percent to 69 percent. The impairment—a one-time charge reflecting that the asset is worth far less than GeneDx paid—is a red flag investors did not see coming.
In the same filing, the company slashed full-year 2026 revenue guidance by 12 percent, from $540–$555 million to $475–$490 million, citing lower-than-expected reimbursement rates and unfavorable product mix. The core problem: genome sequencing tests carry reimbursement rates roughly 50 percent lower than exome tests, a fact that sharply limits revenue per patient.
The Stock Collapse and Investor Losses
On May 4, 2026, WGS stock collapsed 49 percent in a single trading session, closing at $34.51 from $67.93 the prior close, on massive trading volume. Investors who bought during the class period (April 16, 2025 through May 3, 2026) and held through the announcement suffered substantial losses as the market repriced the company's actual earnings power.
An investor who purchased 1,000 shares at $67 in mid-2025 and sold at $34.51 on May 4 lost approximately $32,490 in value. Investors with even larger positions—especially those who bought higher in the class period—suffered six-figure or seven-figure losses. That loss is the basis for participating in the class action.
Who Can Still Join and What It Costs
Although the deadline to serve as lead plaintiff expired August 3, 2026, investors with documented losses exceeding $100,000 can still participate as class members without filing a separate motion. Multiple law firms—including Kessler Topaz, Levi & Korsinsky, Kahn Swick & Foti, and Hagens Berman—are managing claims. There is no upfront cost to participate.
Lawyers work on contingency: they recover a percentage of any settlement or judgment, typically 25 to 33 percent, plus court-approved expenses. If there is no recovery, investors owe nothing. To participate, you will need brokerage statements showing your purchase dates, quantities, and prices during April 16, 2025 through May 4, 2026.
Important Limits and Realities
GeneDx has not admitted liability, and all allegations remain contested. Standard securities class actions proceed through motion practice—including motions to dismiss, summary judgment, and discovery—without an admission from the company. Settlement or trial will determine the actual outcome. Recovery is not guaranteed.
If the case is dismissed on motion, investors receive nothing. If it settles or proceeds to judgment, the fund is typically split among all eligible class members, with larger losses receiving proportionally larger shares. Litigation can take years. A realistic timeline is two to four years from filing to settlement, though some cases resolve faster through negotiation.
Frequently Asked Questions
I bought GeneDx stock in August 2025 at $62 and sold at $35 in May. Can I participate?
Yes, if you purchased between April 16, 2025 and May 4, 2026 and documented your loss. You do not need to be a lead plaintiff; you are automatically part of the class.
What if I bought at $50 and sold at $40—is that enough to participate?
Generally, law firms prioritize claims with losses exceeding $100,000, though smaller losses may be included. Contact one of the managing firms to discuss your specific position.
How long does a class action settlement typically take?
Two to four years is common, depending on court scheduling, discovery, and whether the company settles early or the case proceeds toward trial.
Will I have to testify or go to court?
No. Class members are represented by counsel and the lead plaintiff; individual investors do not typically appear in court unless they volunteer as witnesses.
What if GeneDx wins and the case is dismissed?
Investors receive nothing. However, contingent-fee counsel absorbs the risk, not the class members.